Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III trial of TO-206 in Japanese cedar pollinosis
jRCT2080222528Phase 3Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2014
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of japanese cedar pollen in seasonal allergic rhinitis (SAR) (4 arms), sponsored by Torii Pharmaceutical. Primary endpoints: Efficacy of TO-206 vs placebo and Dose-response and optimal dose determination. Started Jun 2014; status: completed.
02
Drugs
japanese cedar pollen
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2080222528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222528.